Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Decheng Capital LLC

Q1 2024 · 13F-HR

Decheng Capital LLCholdings as filed

Filed 2024-05-14 · accession 0001104659-24-060707

$745.6M
Reported value
22
Positions
2024-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
02083G100NVLSEURAlpine Immune Sciences, Inc.$329.7M44.2%8,317,924CommonSOLE
156944100CGONCG ONCOLOGY INC$239.6M32.1%5,458,810CommonSOLE
98943L107ZNTLZentalis Pharmaceuticals Inc.$33.1M4.44%2,099,583CommonSOLE
452327109ILMNIllumnia, Inc.$17.7M2.38%129,067CommonSOLE
G10830100BYSIBeyondSpring Inc.$17.7M2.37%4,958,143CommonSOLE
03969F109RCUSArcus Biosciences, Inc$16.4M2.20%869,790CommonSOLE
501147102KRYSKRYSTAL BIOTECH INC$11.7M1.57%65,772CommonSOLE
35104E100FDMT4D MOLECULAR THERAPEUTICS IN$11.1M1.49%347,835CommonSOLE
29446K106EQEquillium Inc.$10.3M1.38%4,447,308CommonSOLE
71722W107PHATPHATHOM PHARMACEUTICALS INC$9.0M1.21%850,000CommonSOLE
G4444C102MLTXMOONLAKE IMMUNOTHERAPEUTICS$8.4M1.12%166,600CommonSOLE
22663K107CRNXCRINETICS PHARMACEUTICALS IN$7.4M0.99%157,958CommonSOLE
88025u10910x Genomics, Inc.$7.3M0.99%195,835CommonSOLE
23282W605CYTKCYTOKINETICS INC$6.6M0.88%94,043CommonSOLE
52490G102LEGNLEGEND BIOTECH CORP-ADR$4.8M0.65%86,363CommonSOLE
N5749R1002GHMERUS NV$4.6M0.61%101,798CommonSOLE
05153U107AURAAura Biosciences, Inc.$4.0M0.54%515,555CommonSOLE
229790100HLTHQCue Health Inc.$1.7M0.23%8,980,909CommonSOLE
747324101PYXSPyxis Oncology, Inc (formerly Apexigen)$1.4M0.19%326,810CommonSOLE
00032Q104WHWKAadi Bioscience, Inc.$1.2M0.17%526,329CommonSOLE
81663L200WGSGeneDx Holdings Corp.$945,9040.13%103,604CommonSOLE
04963C209ATRCAtriCure Inc.$815,1650.11%26,797CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.